Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the t...
Publications
2 shownOverall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 10,689
- Institution
- Tokyo National Hospital
External Links
Identifiers
- ORCID
- 0000-0002-6137-073X
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.